A multi centre, open label study to evaluate efficacy and safety of 1000 mg of rituximab on day 1 and 15 in patients with idiopathic thrombocytopenic purpura

Update Il y a 4 ans
Reference:

  • | Country :
  • Australia
  • | organs :
  • -
  • | Specialty :
  • -

Extract


Inclusion criteria

  • Idopathic Thrombocytopenic Purpura

Links